Epidermal growth factor receptor blockers for the treatment of ovarian cancer
<p>Background: This is an update of a previously published version of the review (Issue 10, 2011).</p><p> Epithelial ovarian cancer (EOC) is the seventh most common cause of cancer death among women worldwide. Treatment consists of a combination of surgical debulking and pla...
Main Authors: | Morrison, J, Thoma, C, Goodall, R, Lyons, T, Gaitskell, K, Wiggans, A, Bryant, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
John Wiley & Sons, Ltd
2018
|
Similar Items
-
Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
by: Morrison, J, et al.
Published: (2009) -
Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
by: Maria Bonello, et al.
Published: (2018-12-01) -
Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
by: Morrison, J, et al.
Published: (2008) -
The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01) -
Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer
by: Zhou Q, et al.
Published: (2018-12-01)